Skye Bioscience, Inc.
PublicSkye Bioscience, Inc. is now publicly traded
The data on this page reflects Skye Bioscience, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Feb 12, 2024
Total Funding Raised
$49.99M
Company Overview
Skye Bioscience, Inc. is a clinical-stage biotechnology company that focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
AI Layer
Non-AI
Keywords
Skye Bioscience, Inc. Comparables
Compare Skye Bioscience, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Telara Pharma | 46% | |
| Vyripharm Biopharmaceuticals | 32% |
Skye Bioscience, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Feb 12, 2024 |
Skye Bioscience, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ally Bridge Group | Private Placement |
| Altium Capital | Private Placement |
| 5AM Ventures | Private Placement |
| Driehaus Capital Management | Private Placement |
| Sphera Funds Management | Private Placement |
Recent news
Latest coverage and updates
- acquiresAug 14, 2026
Skye Bioscience was planning to acquire Redx Pharma Plc on Jul 1st '26.
Skye Bioscience, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access